Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
ProShares UltraPro Short Dow30 ETF
SDOW
5
iShares Core S&P 500 ETF
IVV
CN Stock MarketDetailed Quotes
China Meheco Group (600056)
- 10.68
- -0.01-0.09%
Market Closed Jul 18 15:00 CST
15.98BMarket Cap28.71P/E (TTM)
10.72High10.60Low73.85KlotVolume10.69Open10.69Prev Close78.59MTurnover0.49%Turnover Ratio29.83P/E (Static)1.50BShares13.7952wk High1.35P/B15.97BFloat Cap9.3652wk Low11.76Limit Up1.50BShs Float31.02Historical High9.62Limit Down1.12%Amplitude-1.90Historical Low0.11Dividend TTM10.64Avg Price40.82KlotAsk1.00%Div Yield TTM100Lot Size30.69KlotBid
600056 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
600056 Orderflow
Unit: --
600056 Orderflow Trend
IntradayDayWeekMonth
No Data
China Meheco Group (600056) News
The market style is shifting towards trend-following, with a focus on high-positioned hotspots such as computing hardware and innovative pharmaceuticals, presenting opportunities for expansion and extension.
Track the entire lifecycle of the main Sector.
China Meheco Group (600056.SH): Director and General Manager Hu Huidong Resigns
Gelonghui, July 17th | China Meheco Group (600056.SH) announced that the company's Board of Directors has received a written resignation letter from Ms. Hu Huidong, Director and General Manager. Due to a work reassignment, Ms. Hu Huidong has applied to resign from her positions as Director, member of the Board's specialized committees, and General Manager, and will no longer hold any position within the company. As of the date of this announcement, Ms. Hu Huidong does not hold any company stocks.
China Meheco Group (600056.SH): Subsidiary has obtained the drug registration certificate.
On July 11, Gelonghui reported that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd. (referred to as 'Tianfang Pharmaceutical'), received the drug registration certificate for Fudostine Tablets (referred to as 'the drug') issued by the National Medical Products Administration. Fudostine Tablets were developed by Mitsubishi Pharma Corporation in Japan and were launched in Japan in December 2001. Clinically, they are mainly used for treating respiratory diseases such as bronchial asthma, chronic wheezing bronchitis, bronchiectasis, tuberculosis, pneumoconiosis, chronic obstructive pulmonary emphysema, atypical mycobacterial disease, pneumonia, and diffuse panbronchiolitis.
Express News | China Meheco Group: Tianfang Pharmaceutical's Fudositan tablets have obtained the drug registration certificate.
Express News | 16 companies from Jiangsu have been selected as "Top 100 in China's Pharmaceutical Industry."
Innovation in pharmaceuticals fuels new growth: Amid overall revenue pressure, the export growth rate of companies has turned positive.
① In the top 100 enterprises of 2024, 42 companies achieved both revenue and profit growth, with 15 companies growing by more than 10%. ② After two consecutive years of negative growth, the export delivery value growth rate of the top 100 enterprises in 2024 shows a significant rebound, with a year-on-year increase of 9.4%.
Market Insights
Tariff Storm Hits: Hedge with ETFs? Tariff Storm Hits: Hedge with ETFs?
The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios. The U.S. has sparked a tariff storm, triggering global market volatility. When the market fluctuates violently, more investment opportunities often appear. Compared with choosing individual stocks, investing in ETFs of the broader market can more easily capture opportunities for market reversals.
Disclaimer: Among the U.S. stock market index ETFs: EFF, which is in the top 3 in terms of asset size among the fear index ETFs; the top 3 ETFs in terms of asset size among the S&P 500 index ETFs; and the corresponding leveraged ETFs; the top 4 ETFs in terms of asset size among the Nasdaq ETFs; and the top 3 ETFs in terms of asset size among the Dow Jones Index.
This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors' financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. FUTU makes no representation or warranty as to its adequacy, completeness, accuracy or timeline for any particular purpose of the above content.
Instutional holding and portfolio information provided is based data in 13f filings. The composition provided is updated on a significant delay and may be incomplete. It is not possible to replicate the timing or exact holdings and portfolios.
Unlock Now
Discussing
Focus on tariff dynamics! How to plan most securely in the near future?
Recently, Trump's tariffs have sparked controversy again. Trump stated that the United States would impose a 100% tariff on Russia, a 30% ta
Food流油
Apr 14 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"